97P Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)

C. Yoo, J.O. Park, K-P. Kim, J. Hyung,B-Y. Ryoo, J.Y. Hong, S.H. Shin,T.J. Song, D. Oh,W. lee, B.J. Kwak, J.H. Lee, D.W. Hwang

Annals of Oncology(2023)

引用 0|浏览2
暂无评分
关键词
biliary tract cancer,neoadjuvant durvalumab,gemcitabine,cisplatin,open-label
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要